Aptose Biosciences (APTO) Misses Q2 EPS by 215c

Aptose Biosciences (NASDAQ: APTO) reported Q2 EPS of ($2.27), $2.15 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Aptose Biosciences (APTO) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• ZTO Express (ZTO) Tops Q2 EPS by 379c
• Baidu (BIDU) PT Lowered to $150 at Benchmark on Near-Term Margin Concerns